Lincoln Pharma Clarifies Identical Standalone & Consolidated Q2 FY26 Results
Lincoln Pharmaceuticals Limited clarified identical standalone and consolidated financial results for the quarter ended September 30, 2025. This was due to its subsidiary having no financial transactions during the period. The clarification was provided to the NSE on January 8, 2026.
This is a routine clarification regarding the format of financial results and does not introduce any new material financial information or strategic changes.
The announcement is a clarification of previously submitted financial results and does not contain new positive or negative financial information.
Lincoln Pharmaceuticals Limited has provided a clarification to the National Stock Exchange of India (NSE) regarding its financial results for the quarter ended September 30, 2025. The company explained that the standalone and consolidated financial statements for the period, submitted on November 13, 2025, showed identical figures in the Profit and Loss statements.
This similarity occurred because Lincoln Pharmaceuticals Limited's sole subsidiary had no financial transactions during the second quarter of the fiscal year 2026. Consequently, the consolidated financial results mirrored the standalone results as there were no additional financial activities at the subsidiary level to report.
The clarification was issued in response to an email from the NSE dated January 7, 2026, concerning the format of the submitted financial results.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other results related. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.